Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index; 7 of the 25 sources its claims cite were checked for support.

Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services

Open access

Abstract

OBJECTIVES: Glucagon-like peptide 1 receptor agonists (GLP1-RA) are indicated for the treatment of type 2 diabetes and more recently for weight loss. The aim of this study was to assess the risks associated with GLP1-RA exposure during early pregnancy. DESIGN: This multicentre, observational prospective cohort study compared pregnancy outcomes in women exposed to GLP1-RA in early pregnancy either for diabetes or obesity treatment with those in two reference groups: (1) women with diabetes exposed to at least one non-GLP1-RA antidiabetic drug during the first trimester and (2) a reference group of overweight/obese women without diabetes, between 2009 and 2022. SETTING: Data were collected from the databases of six Teratology Information Services. PARTICIPANTS: This study included 168 pregnancies of women exposed to GLP1-RA during the first trimester, alongside a reference group of 156 pregnancies of women with diabetes and 163 pregnancies of overweight/obese women. RESULTS: Exposure to GLP1-RA in the first trimester was not associated with a risk of major birth defects when compared with diabetes (2.6% vs 2.3%; adjusted OR, 0.98 (95% CI, 0.16 to 5.82)) or to overweight/obese (2.6% vs 3.9%; adjusted OR 0.54 (0.11 to 2.75)). For the GLP1-RA group, cumulative incidence for live births, pregnancy losses and pregnancy terminations was 59%, 23% and 18%, respectively. In the diabetes reference group, corresponding estimates were 69%, 26% and 6%, while in the overweight/obese reference group, they were 63%, 29% and 8%, respectively. Cox proportional cause-specific hazard models indicated no increased risk of pregnancy losses in the GLP1-RA versus the diabetes and the overweight/obese reference groups, in both crude and adjusted analyses. CONCLUSIONS: This study offers reassurance in cases of inadvertent exposure to GLP1-RA during the first trimester of pregnancy. Due to the limited sample size, larger studies are required to validate these findings.

Overview

CoChat Summary

TL;DR

In this multicentre prospective cohort of 168 first-trimester GLP1 receptor agonist (GLP1-RA) exposures, the study found no increased risk of major birth defects or pregnancy loss versus two reference groups. The authors conclude the findings are reassuring for inadvertent early-pregnancy exposure, but the sample was too small for definitive conclusions.

Key findings

  • Among 168 GLP1-RA-exposed pregnancies, major birth defects occurred in 2.6%; compared with 2.3% in women with diabetes, the adjusted OR was 0.98 (95% CI, 0.16 to 5.82), and compared with overweight/obese women it was 0.54 (95% CI, 0.11 to 2.75).
  • Cumulative incidence in the GLP1-RA group was 59% live births, 23% pregnancy losses, and 18% pregnancy terminations; the corresponding estimates were 69%/26%/6% in the diabetes reference group and 63%/29%/8% in the overweight/obese reference group.
  • Cause-specific Cox models found no increased risk of pregnancy loss versus either reference group; however, termination of pregnancy was higher versus the diabetes group (adjusted HR 3.89; 95% CI, 1.48 to 10.2) but not versus the overweight/obese group (adjusted HR 1.39; 95% CI, 0.66 to 2.93).
  • In the exposed group, liraglutide was most common (n=99), followed by semaglutide (n=51), dulaglutide (n=11), and exenatide (n=7); 70% used GLP1-RA for weight loss.

Methods

  • Multicentre, observational, prospective cohort study using data from six Teratology Information Services in five countries (Germany, Israel, Italy, Switzerland, UK), covering pregnancies from 2009 to 2022.
  • Included 168 pregnancies with first-trimester GLP1-RA exposure and two reference groups: 156 pregnancies in women with diabetes exposed to non-GLP1-RA antidiabetic drugs, and 163 pregnancies in overweight/obese women without diabetes.
  • Main analyses used multivariable logistic regression for major birth defects and cause-specific Cox proportional hazard models with cumulative incidence functions for pregnancy loss and termination, adjusting for maternal age, prior pregnancies, polymedication, and other listed covariates.

Limitations

  • The paper states the sample size was limited and “not large enough to draw firm and definitive conclusions.”
  • The authors state that HbA1c and other severity markers were not systematically available, limiting assessment of diabetes severity.
  • The text makes evident that GLP1-RA were analyzed as a single homogeneous group, so drug-specific risks for individual agents could not be well assessed; it also notes that exposure often stopped early in gestation, so full first-trimester exposure was not always present.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2023-083550

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Cumulative incidences of pregnancy outcomes with live birth (LB), pregnancy losses (PL) and pregnancy termination (TOP) in women exposed to glucagon-like peptide 1 receptor agonists, the diabetes reference group and the overweight/obesity reference group.
Figure 1 Cumulative incidences of pregnancy outcomes with live birth (LB), pregnancy losses (PL) and pregnancy termination (TOP) in women exposed to glucagon-like peptide 1 receptor agonists, the diabetes reference group and the overweight/obesity reference group.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 9 Not checked · 52 Own results and interpretations

16 more claims

Create a free account to see all 67 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 37
  • It may state two separate claims as one. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 2

  1. Lau, 2023, Semaglutid in der Adipositastherapie: Viel Diskussionsstoff, Dtsch Arztebl, 120, A
  2. Organization of Teratology Information Specialists (OTIS) . Mother to baby | fact sheets [Internet]. In: Critical periods of development. 2021. Available: https://www.ncbi.nlm.nih.gov/books/NBK582659/

Cited by

See all 110

Metadata

Authors
Dao, K., Shechtman, S., Weber-Schoendorfer, C., Diav-Citrin, O., Murad, R. H., Berlin, M., Hazan, A., Richardson, J. L., Eleftheriou, G., Rousson, V., Diezi, L., Haefliger, D., Simões-Wüst, A. P., Addor, M.-C., Baud, D., Lamine, F., Panchaud, A., Buclin, T., Girardin, F. R., & Winterfeld, U.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • Israel Ministry of Health (IL)
  • Charité - Universitätsmedizin Berlin, Pharmakovigilanzzentrum Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany
  • The Israeli Teratology Information Service, Ministry of Health, Jerusalem, Israel
  • Tel Aviv University (IL)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • Ospedale Papa Giovanni XXIII (IT)
  • University of Lausanne (CH)
  • Swiss Teratogen Information Service and Clinical Pharmacology Service, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland
  • Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland
  • Endocrinology, Diabetes and Metabolism Service, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
  • University of Bern (CH)
Corresponding author
Winterfeld, Ursula
Venue
BMJ Open
Publisher
BMJ
Published
2024-04
Volume
14
Issue
4
Pages
e083550
ISSN
2044-6055 (ISSN-L)
OpenAlex
W4395468671
Cited by
110
References
24
Citations by year
2026: 49 · 2025: 54 · 2024: 7
FWCI
45.33
Type
journal article
Language
en
Open access
Locations
  • BMJ Open (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion, cc-by)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • IRIS (submittedVersion, cc-by)
  • HighWire Press Open Archive (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Funders
Swiss National Science Foundation (SNSF 320030_214844)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
Keywords
GLP-1 receptor agonists, early pregnancy, teratogenicity, congenital malformations, miscarriage, live birth, reproductive safety, type 2 diabetes, obesity, antidiabetic drugs, anti-obesity drugs
MeSH terms
Abnormalities, Drug-Induced, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Obesity, Pregnancy, Pregnancy Complications, Pregnancy in Diabetics, Pregnancy Outcome, Pregnancy Trimester, First, Prospective Studies, Databases, Factual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. https://app.cochat.ai/papers/10.1136/bmjopen-2023-083550
The paper
Dao, K., Shechtman, S., Weber-Schoendorfer, C., Diav-Citrin, O., Murad, R. H., Berlin, M., Hazan, A., Richardson, J. L., Eleftheriou, G., Rousson, V., Diezi, L., Haefliger, D., Simões-Wüst, A. P., Addor, M.-C., Baud, D., Lamine, F., Panchaud, A., Buclin, T., Girardin, F. R., & Winterfeld, U. (2024). Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. https://doi.org/10.1136/bmjopen-2023-083550

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.